After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 ...

Eli Lilly is aware of this fact, which helps explain why it acquired Adverum Biotechnologies in late 2025 and just agreed to ...

Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor ...

Nimbus will use its AI to help identify drug candidates, while Lilly will contribute its metabolic-disease expertise to ...

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...

Eli Lilly is getting its hands on a promising pipeline candidate thanks to an acquisition. The stock may not gain much more ...

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

SHANGHAI, Dec 8 (Reuters) – Eli Lilly and Co.’s popular drug Mounjaro will be added to China’s state-run health insurance scheme from Jan. 1 for patients with type 2 diabetes, the National Healthcare ...

Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to ...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...